GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing ...

India-based Syngene International on Monday said it will invest around $50 million on a biologics facility in the Baltimore area, expanding its global manufacturing footprint as companies look to ...

As of March 10, Syngene International Ltd. announces its first biologics facility purchase in the USA. The site houses several monoclonal antibody (mAbs) production lines. Syngene USA Inc., a ...

Emergent BioSolutions (EBS) is strengthening relationships with partners across sectors and continuing its commitment to ensuring widespread ...

NASHVILLE, Tenn. -- — Josh Hubbard made six 3-pointers and scored 26 points, and No. 10 seed Mississippi State cruised to a 91-62 victory over 15th-seeded LSU in the first round of the SEC ...

In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, and manufacturing organization (CRDMO), acquired its first biologics site in ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Syngene International Ltd. is a Public Limited Listed company incorporated on 18/11/1993 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) ...

Syngene International Limited is an integrated research development and manufacturing services organization serving global pharmaceutical biotechnology nutrition animal health consumer goods and ...

Syngene International acquires its first US manufacturing facility for USD 50 million, expanding its reach in human and animal health markets. Mar 10, 2025 20:59 Syngene CEO Jonathan Hunt Steps Down, ...

Intimation of investment in Syngene USA Inc a wholly owned subsidiary of the Company ...